Adam Simpson, Icosavax CEO
December 14, 2022 10:52 AM ESTUpdated 11:11 AM
R&D

Icosavax push­es for­ward with an RSV can­di­date af­ter Covid-19 vac­cine flop

Tyler Patchen

News Reporter

Seat­tle-based Icosavax was at­tempt­ing to make a splash ear­li­er this year by show­ing off da­ta for its Covid-19 vac­cine can­di­date, but it end­ed up hit­ting …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times